Skip to main content

User account menu

  • My EPI-CE Documentation
  • Log in

Top navigation

  • Contact Us
  • +49 89 416 17270
Bio-Techne Exosome logo

User account menu

  • My EPI-CE Documentation
  • Log in

Main navigation

  • Laboratories
    • ExoDx™ Prostate EPI-CE IVD
  • Physicians
    • ExoDx™ Prostate Test
    • Challenge of Prostate Cancer
    • Physician FAQs
    • What are Exosomes
    • Publications and Abstracts
  • Patients
    • The ExoDx Prostate Test
    • The ExoDx Prostate Test
    • Understanding PSA Levels
    • About Prostate Cancer
  • Pharma Services
    • Working with Us
    • Biomarker Discovery
    • Assay Development
    • Exosome Enrichment Capabilities
    • Companion Diagnostics (CDx) and Clinical Trial Support
  • Our Technology
    • Our Technology
    • Sensitivity to RNA/DNA
    • Extraction Procedures
    • Superiority to cfDNA and CTCs
  • News & Resources
    • Press
    • Webinars
    • Events

Top navigation

  • Contact Us
  • +49 89 416 17270

Investors

ExosomeDx is now part of Bio-Techne.  Please see our Bio-Techne investors site.

  • Bio-Techne Investors

+49 89 416 17270
exosomedx.info@bio-techne.com
Exosome Diagnostics GmbH
Am Klopferspitz 19a
82152 Martinsried
Germany

Footer menu

  • About Bio-Techne
  • Management Team
  • Careers
  • Investors
  • Corporate Responsibility
  • Accreditation and Licensure

Social navigation

  • Facebook
  • Twitter
  • LinkedIn

Iso LogoThe EPI-CE test was developed by Exosome Diagnostics, Inc. according to the European Union directive for in-vitro diagnostic devices IVDD (98/79/EC) and the performance characteristics determined by Exosome Diagnostics, Inc. The test performance has been verified in Exosome Diagnostics GmbH's clinical laboratories in Martinsried, Germany. Exosome Diagnostics GmbH is accredited by Dakks to ISO 15189. Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2024 ExoDx

Bottom footer navigation

  • Privacy Policy
  • Datanschutzerklärung
  • Impressum